What is the appropriate next management for an 81‑year‑old woman with type 2 diabetes, hemoglobin A1c 6.9%, impaired renal function (elevated BUN, reduced eGFR) and significant albuminuria/proteinuria who is currently taking atenolol, aspirin, atorvastatin, gabapentin, insulin, semaglutide, and valsartan (Diovan)?

Management of Diabetic Kidney Disease in an 81-Year-Old Woman

Add finerenone to this patient's current regimen, as she has type 2 diabetes with eGFR 50 mL/min/1.73 m² and severely elevated albuminuria (ACR 577 mg/g) despite maximum tolerated RAS inhibition with valsartan. 1

Immediate Priority: Add Nonsteroidal Mineralocorticoid Receptor Antagonist

The 2022 ADA-KDIGO consensus guidelines specifically recommend adding a nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) like finerenone for patients with type 2 diabetes, eGFR ≥25 mL/min/1.73 m², and albuminuria ≥30 mg/g despite maximum tolerated RAS inhibitor therapy. 1 This patient meets all criteria with her ACR of 577 mg/g and eGFR of 50 mL/min/1.73 m².

Finerenone Dosing Protocol

• Start finerenone at 10 mg daily (not 20 mg) because her eGFR is between 25-60 mL/min/1.73 m², and ensure serum potassium is ≤5.0 mmol/L before initiation. 1

• Check potassium 4 weeks after starting and regularly thereafter; uptitrate to 20 mg daily if potassium remains <4.8 mmol/L. 1

• Withhold finerenone if potassium rises >5.5 mmol/L, and restart at 10 mg daily once potassium is ≤5.0 mmol/L. 1

• Continue valsartan (Diovan) at current dose—do not combine with an ACE inhibitor, as dual RAS blockade increases hyperkalemia and acute kidney injury without added benefit. 1

Optimize Current Diabetes Medications

Semaglutide: Continue Without Adjustment

• Continue semaglutide at current dose as GLP-1 receptor agonists can be used at eGFR <30 mL/min/1.73 m² without dose adjustment and provide proven cardiovascular and renal benefits. 2

• Her A1C of 6.9% indicates good glycemic control, but semaglutide offers cardiorenal protection beyond glucose lowering. 2

Insulin: Consider Dose Reduction

• Reduce insulin doses by approximately 25% or more given her eGFR of 50 mL/min/1.73 m², as decreased renal gluconeogenesis and reduced insulin clearance increase hypoglycemia risk. 2

• Monitor for hypoglycemia more frequently, especially with her already well-controlled A1C of 6.9%. 2

• In elderly patients with CKD stage 3, insulin requires careful titration due to altered pharmacokinetics. 2

Medication Safety Review

Gabapentin: Dose Adjustment Required

• Reduce gabapentin dose based on her creatinine clearance, as gabapentin is renally eliminated and accumulates in renal impairment. 3

• Gabapentin clearance is directly proportional to creatinine clearance, and elderly patients show reduced clearance even independent of renal function. 3

Atenolol: Monitor Carefully

• Continue atenolol but monitor for bradycardia and hypotension, particularly after adding finerenone, which may cause additional blood pressure lowering. 4

• Valsartan requires no dose adjustment for mild-to-moderate renal impairment (her eGFR 50 qualifies as stage 3a CKD). 4

Aspirin and Atorvastatin: Continue

• Continue both medications as part of comprehensive cardiovascular risk reduction. 1

Monitoring Plan

Renal Function and Electrolytes

• Monitor eGFR, potassium, and HbA1c every 3 months given her CKD stage 3a. 2

• Check potassium 4 weeks after starting finerenone and with any dose adjustment. 1

• Screen for anemia, secondary hyperparathyroidism, and metabolic bone disease as recommended for CKD stage 3. 2

Blood Pressure Target

• Target blood pressure <130/80 mmHg with her current valsartan plus the addition of finerenone for renoprotection. 2

• Monitor for symptomatic hypotension, particularly in the first weeks after adding finerenone. 1, 4

Key Clinical Pitfalls to Avoid

• Do not add an ACE inhibitor to her ARB (valsartan)—dual RAS blockade increases adverse events without benefit. 1

• Do not initiate SGLT-2 inhibitors at her current eGFR of 50 mL/min/1.73 m²—while they could have been started earlier, guidelines suggest not initiating canagliflozin at eGFR <30 and empagliflozin at eGFR <45 mL/min/1.73 m². 2 Given her age (81) and already good glycemic control, the risk-benefit ratio favors focusing on finerenone for renoprotection.

• Avoid overtreatment of diabetes—her A1C of 6.9% is already at or below target for an 81-year-old with CKD; more relaxed targets (7.5-8.5%) are appropriate for frail elderly patients to minimize hypoglycemia risk. 5, 6

• Monitor for hypoglycemia vigilantly given her age, CKD, and combination of insulin plus semaglutide. 2